Genmab A/S (GMAB) Stock Forecast & Price Target

$34.22 +0.01 (+0.01%)

As of 10:26 AM Eastern

Compare

Genmab A/S - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 13 Analyst Ratings

Sell
0

Hold
3

Buy
10

Based on 13 Wall Street analysts who have issued ratings for Genmab A/S in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 3 have given a hold rating, 9 have given a buy rating, and 1 has given a strong buy rating for GMAB.

Consensus Price Target

$39.50
15.41% Upside

According to the 13 analysts' twelve-month price targets for Genmab A/S, the average price target is $39.50. The highest price target for GMAB is $43.00, while the lowest price target for GMAB is $32.00. The average price target represents a forecasted upside of 15.41% from the current price of $34.23.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for GMAB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Genmab A/S and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GMAB Analyst Ratings Over Time

Type	Current Forecast 9/3/25 to 9/3/26	1 Month Ago 8/4/25 to 8/4/26	3 Months Ago 6/5/25 to 6/5/26	1 Year Ago 9/3/24 to 9/3/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	8 Buy rating(s)	6 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$39.50	$39.28	$37.93	$37.60
Forecasted Upside	15.41% Upside	35.35% Upside	50.81% Upside	38.85% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

GMAB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GMAB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Genmab A/S Stock vs. The Competition

Type	Genmab A/S	Healthcare Companies	Broader Market
Consensus Rating Score	2.85	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	15.43% Upside	815.26% Upside	14.07% Upside
News Sentiment Rating	Positive News See Recent GMAB News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/1/2026	Weiss Ratings 5 of 5 stars		Upgrade	Hold (C) ➝ Hold (C+)
8/7/2026	Guggenheim 5 of 5 stars	Michael Schmidt 5 of 5 stars	Boost Target	Buy	$40.00 ➝ $42.00	+35.33%
7/22/2026	New Street Research 4 of 5 stars		Set Target		$43.00	+51.62%
7/22/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yaron Werber Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$32.00 ➝ $43.00	+51.62%
7/2/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Raghuram Selvaraju Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$38.00 ➝ $40.00	+44.72%
5/27/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Buy	$40.00	+48.75%
4/22/2026	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
4/22/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Neutral ➝ Buy
3/27/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kalpit Patel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$32.00	+22.94%
3/2/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eva Fortea Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Overweight	$40.00	+35.87%
My top 3 AI picks for the next decade (Ad) Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade. Click here to get all three AI stock names from Alexander Green
2/17/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Benjamin Jackson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$41.50	+38.20%
2/16/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Judah Frommer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Equal Weight	$34.00	+13.22%
10/31/2025	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
10/27/2025	Johnson Rice Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
4/1/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	J. Smith Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Market Perform ➝ Underperform
3/11/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Phipps Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
2/13/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jonathan Chang Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$27.00	+37.13%
11/8/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform	$46.00 ➝ $48.00	+110.25%
10/8/2024	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Qize Ding Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 10:13 AM ET.

Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, August 30, 2026. Please send any questions or comments about these Genmab A/S pros and cons to contact@marketbeat.com.

Genmab A/S
Bull Case

Here are some ways that investors could benefit from investing in Genmab A/S:

The current stock price is around $27, which is significantly lower than its 52-week high of $35.43, indicating potential for price appreciation.
Genmab A/S reported earnings per share (EPS) of $0.54 for the latest quarter, exceeding analyst expectations, which reflects strong financial performance.
The company has a solid market capitalization of approximately $18.60 billion, suggesting a stable position in the biotechnology sector.
Analysts have a consensus rating of "Moderate Buy" with a price target of around $39.28, indicating positive sentiment and potential upside.
Genmab A/S has a robust current ratio of 2.18, indicating good short-term financial health and the ability to cover its liabilities.

Genmab A/S
Bear Case

Investors should be bearish about investing in Genmab A/S for these reasons:

The company has a debt-to-equity ratio of 0.87, which, while manageable, indicates a reliance on debt financing that could pose risks in volatile markets.
Despite recent upgrades from analysts, the stock has shown volatility, with a beta of 0.83, suggesting it may not be as stable as some investors prefer.
Genmab A/S's PEG ratio of 1.84 indicates that the stock may be overvalued relative to its growth rate, which could deter value-focused investors.
Institutional ownership is relatively low at 7.07%, which may indicate a lack of confidence from larger investors in the company's future prospects.
The company operates in a highly competitive biotechnology sector, which can lead to unpredictable market conditions and potential challenges in maintaining its market position.

GMAB Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Genmab A/S is $39.50, with a high forecast of $43.00 and a low forecast of $32.00.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There are currently 3 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GMAB shares.

According to analysts, Genmab A/S's stock has a predicted upside of 15.41% based on their 12-month stock forecasts.

Over the previous 90 days, Genmab A/S's stock had 4 upgrades by analysts.

Genmab A/S has been rated by research analysts at Guggenheim, HC Wainwright, New Street Research, TD Cowen, and Weiss Ratings in the past 90 days.

Analysts like Genmab A/S more than other "healthcare" companies. The consensus rating for Genmab A/S is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how GMAB compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Genmab A/S Recommendations

MarketBeat monitors more than a dozen sources for Genmab A/S analyst ratings, with the most recent rating issued on 9/1/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genmab A/S (GMAB) Stock Forecast & Price Target

Genmab A/S - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

GMAB Analyst Ratings Over Time

GMAB Analyst Recommendations By Month

GMAB Price Targets by Month

Genmab A/S Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained

Genmab A/S
Bull Case

Genmab A/S
Bear Case

GMAB Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Genmab A/S Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genmab A/S (GMAB) Stock Forecast & Price Target

Genmab A/S - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

GMAB Analyst Ratings Over Time

GMAB Analyst Recommendations By Month

GMAB Price Targets by Month

Genmab A/S Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained

Genmab A/S Bull Case

Genmab A/S Bear Case

GMAB Forecast - Frequently Asked Questions

What is Genmab A/S's forecast for 2026?

Should I buy or sell Genmab A/S stock right now?

Does Genmab A/S's stock price have much upside?

Has Genmab A/S been upgraded by Wall Street analysts recently?

What analysts cover Genmab A/S?

Do Wall Street analysts like Genmab A/S more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Genmab A/S Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Genmab A/S
Bull Case

Genmab A/S
Bear Case